Inhibiteurs de la 5-alpha réductase : Questions médicales fréquentes
Nom anglais: 5-alpha Reductase Inhibitors
Descriptor UI:D058891
Tree Number:D27.505.696.399.450.855.200
Termes MeSH sélectionnés :
Cell Line
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la 5-alpha réductase : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la 5-alpha réductase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la 5-alpha réductase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-15",
"dateModified": "2025-04-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la 5-alpha réductase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse des stéroïdes",
"url": "https://questionsmedicales.fr/mesh/D065088",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse des stéroïdes",
"code": {
"@type": "MedicalCode",
"code": "D065088",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.399.450.855"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la 5-alpha réductase",
"alternateName": "5-alpha Reductase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D058891",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Francesco Del Giudice",
"url": "https://questionsmedicales.fr/author/Francesco%20Del%20Giudice",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Sapienza University of Rome, Rome, Italy."
}
},
{
"@type": "Person",
"name": "James L Mohler",
"url": "https://questionsmedicales.fr/author/James%20L%20Mohler",
"affiliation": {
"@type": "Organization",
"name": "Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA."
}
},
{
"@type": "Person",
"name": "Thiraphat Saengmearnuparp",
"url": "https://questionsmedicales.fr/author/Thiraphat%20Saengmearnuparp",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand."
}
},
{
"@type": "Person",
"name": "Bannakij Lojanapiwat",
"url": "https://questionsmedicales.fr/author/Bannakij%20Lojanapiwat",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand."
}
},
{
"@type": "Person",
"name": "Nipon Chattipakorn",
"url": "https://questionsmedicales.fr/author/Nipon%20Chattipakorn",
"affiliation": {
"@type": "Organization",
"name": "Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Transmitochondrial Cybrid Generation Using Cancer Cell Lines.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/37010306",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3791/65186"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cell line authentication: a necessity for reproducible biomedical research.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35758134",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.15252/embj.2022111307"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comprehensive Analysis of Oligo/Polysialylglycoconjugates in Cancer Cell Lines.",
"datePublished": "2022-05-16",
"url": "https://questionsmedicales.fr/article/35628382",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23105569"
}
},
{
"@type": "ScholarlyArticle",
"name": "Universal cell donor lines: A review of the current research.",
"datePublished": "2023-10-12",
"url": "https://questionsmedicales.fr/article/37832541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.stemcr.2023.09.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multi-omics data of gastric cancer cell lines.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37081404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12863-023-01122-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hormones, substituts d'hormones et antagonistes d'hormones",
"item": "https://questionsmedicales.fr/mesh/D006730"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antihormones",
"item": "https://questionsmedicales.fr/mesh/D006727"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs de la synthèse des stéroïdes",
"item": "https://questionsmedicales.fr/mesh/D065088"
},
{
"@type": "ListItem",
"position": 8,
"name": "Inhibiteurs de la 5-alpha réductase",
"item": "https://questionsmedicales.fr/mesh/D058891"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la 5-alpha réductase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la 5-alpha réductase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la 5-alpha réductase",
"description": "Comment diagnostiquer une hyperplasie bénigne de la prostate ?\nQuels tests sont utilisés pour évaluer la DHT ?\nQuels symptômes indiquent un besoin d'inhibiteurs ?\nComment évaluer l'efficacité des inhibiteurs ?",
"url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cell+Line&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la 5-alpha réductase",
"description": "Quels sont les symptômes de l'hyperplasie bénigne de la prostate ?\nLa calvitie est-elle un symptôme lié à la DHT ?\nQuels effets secondaires peuvent survenir ?\nLes inhibiteurs affectent-ils la libido ?",
"url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cell+Line&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la 5-alpha réductase",
"description": "Peut-on prévenir l'hyperplasie bénigne de la prostate ?\nY a-t-il des mesures préventives pour la calvitie ?\nLes inhibiteurs peuvent-ils être utilisés préventivement ?\nQuels changements de mode de vie sont recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cell+Line&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la 5-alpha réductase",
"description": "Quels médicaments sont des inhibiteurs de la 5-alpha réductase ?\nComment les inhibiteurs agissent-ils ?\nQuelle est la durée du traitement ?\nLes inhibiteurs sont-ils efficaces pour la calvitie ?",
"url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cell+Line&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la 5-alpha réductase",
"description": "Quelles complications peuvent survenir avec les inhibiteurs ?\nLes inhibiteurs augmentent-ils le risque de cancer ?\nComment gérer les effets secondaires ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cell+Line&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la 5-alpha réductase",
"description": "Quels sont les facteurs de risque de l'hyperplasie bénigne ?\nLa génétique joue-t-elle un rôle dans la calvitie ?\nLe mode de vie influence-t-il la DHT ?\nL'âge est-il un facteur de risque pour la calvitie ?",
"url": "https://questionsmedicales.fr/mesh/D058891?mesh_terms=Cell+Line&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hyperplasie bénigne de la prostate ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen physique, des tests urinaires et un dosage du PSA aident au diagnostic."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la DHT ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage sanguin de la DHT peut être effectué pour évaluer les niveaux hormonaux."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'inhibiteurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes urinaires comme des difficultés à uriner peuvent indiquer un besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des inhibiteurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'amélioration des symptômes et la réduction du PSA."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hyperplasie bénigne de la prostate ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des mictions fréquentes, un jet urinaire faible et des douleurs."
}
},
{
"@type": "Question",
"name": "La calvitie est-elle un symptôme lié à la DHT ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la DHT est impliquée dans la perte de cheveux androgénétique chez les hommes."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent la dysfonction érectile, la réduction de la libido et la gynécomastie."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs affectent-ils la libido ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent éprouver une diminution de la libido en raison des inhibiteurs."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hyperplasie bénigne de la prostate ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent aider à réduire le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour la calvitie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins capillaires appropriés et des traitements précoces peuvent aider à prévenir la calvitie."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs peuvent-ils être utilisés préventivement ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont généralement pas utilisés en prévention, mais pour traiter des symptômes existants."
}
},
{
"@type": "Question",
"name": "Quels changements de mode de vie sont recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et la gestion du stress sont conseillés."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inhibiteurs de la 5-alpha réductase ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments comme le finastéride et le dutastéride sont des inhibiteurs connus."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs agissent-ils ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent la conversion de la testostérone en DHT, réduisant ainsi les symptômes."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut durer plusieurs mois avant d'observer des résultats significatifs."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils efficaces pour la calvitie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent ralentir la perte de cheveux et favoriser la repousse chez certains patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les inhibiteurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la dysfonction érectile et des troubles hormonaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs augmentent-ils le risque de cancer ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent des résultats contradictoires, mais un suivi médical est recommandé."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consulter un médecin pour ajuster le traitement ou envisager des alternatives est conseillé."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles après l'arrêt du traitement, mais pas toutes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'hyperplasie bénigne ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, l'obésité et des antécédents familiaux augmentent le risque d'hyperplasie bénigne."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans la calvitie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la génétique est un facteur majeur dans la perte de cheveux androgénétique."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il la DHT ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les niveaux de DHT."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour la calvitie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de calvitie augmente avec l'âge, surtout chez les hommes."
}
}
]
}
]
}
In recent years, the number of studies dedicated to ascertaining the connection between mitochondria and cancer has significantly risen. However, more efforts are still needed to fully understand the ...
Immortalized or continuous cell lines are invaluable tools in basic and preclinical research. However, the widespread use of misidentified cell lines is a serious threat to scientific reproducibility....
In cancer cells, cell-surface sialylation is altered, including a change in oligo/polysialic acid (oligo/polySia) structures. Since they are unique and rarely expressed in normal cells, oligo/polySia ...
Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) hold promise for transplantation medicine. Diverse human leukocyte antigen (HLA) profiles necessitate autologous cells or m...
Gastric cancer (GC) is the fourth most common cancer worldwide, with the highest incidence and mortality regardless of sex. Despite technological advances in diagnosing and treating gastric cancer, GC...
Multiomic data, such as RNA-seq, Exome-seq, and ChIP-seq, were produced in gastric cancer and normal cell lines. RNA-seq data were generated from nine GC and one normal gastric cell line, mapped to a ...
A more pronounced characteristic of cancer cells is the energy dependence on glucose, which mitigated by glucose transporters. The comprehension of the regulatory mechanisms behind the Warburg effect ...
Flow cytometry with propidium iodide staining was used to determine cell apoptosis. For glucose uptake detection, the "GOD-PAP" enzymatic colorimetric test was used to measure the direct glucose level...
According to qRT-PCR analysis, the levels of GLUT1 and GLUT3 mRNA were lower in the group that received Apigenin relative to the control group. The Apigenin treatment of SW1736 cells decreased protein...
These findings demonstrate the possibility of targeting the glucose facilitators' pathway for making thyroid cancer cells more susceptible to programmed cell death....
Gastrointestinal (GI) cancers constitute the largest portion of all human cancers, and the most prevalent GI cancers in China are colorectal cancer (CRC), gastric cancer (GC), and hepatocellular carci...
Prostate cell lines from diverse backgrounds are important to addressing disparities in prostate cancer (PCa) incidence and mortality rates among Black men. ACRJ-PC28 was developed from a transrectal ...
The aim of this study is to provide a comprehensive characterization of stemness in pancreatic ductal adenocarcinoma (PDAC) cell lines. Seventeen cell lines were evaluated for the expression of cancer...
The hallmarks of biological processes that underlie the development of cancer have been long recognized, yet, existing therapeutic treatments cannot prevent cancer from continuing to be one of the lea...